Version 1
: Received: 21 August 2023 / Approved: 21 August 2023 / Online: 22 August 2023 (07:58:07 CEST)
Version 2
: Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (02:54:00 CEST)
Version 3
: Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (10:00:17 CET)
Version 4
: Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:52:59 CET)
Version 5
: Received: 21 March 2024 / Approved: 22 March 2024 / Online: 22 March 2024 (12:06:13 CET)
How to cite:
Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v5
Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints 2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v5
Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v5
APA Style
Renteln, M. (2024). A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints. https://doi.org/10.20944/preprints202308.1536.v5
Chicago/Turabian Style
Renteln, M. 2024 "A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations" Preprints. https://doi.org/10.20944/preprints202308.1536.v5
Abstract
Over the last several years, large-scale cancer genomics studies involving multi region, multi-sample sequencing indicate that most or at least many cancer patients may have one or more “clonal" mutations in their tumors.Clonal mutations are those that are present in all of a patient’s cancer cells.They can be identified via multiregion, multisample biopsies - or circulating tumor cells/cell-free DNA.Achilles Therapeutics is currently the only company targeting patient-specific, clonal mutations.They have opted to utilize an immunotherapy approach.However, I recently devised another approach for exploiting clonal mutations called “Oncolytic Vector Replication Contingent on Omnipresent Mutation Engagement” (OVERCOME).It is based on the identification of patient-specific, clonal mutations and targeting them using a bioengineered facultative intracellular bacterium.It would be initially non-replicating, but transiently regain the ability to replicate (and also transiently become hyper-virulent) upon mutation detection via molecular switches.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
